mL. 6 Taking these into consideration, the severity of eosinophilia might serve as a useful indicator for an early tentative diagnosis. This study aimed at clarification of the relationship between peripheral eosinophil count and incidence of a HEAD to make a quick diagnosis.
The blood samples from the patients who were 20 years of age and older examined for the complete blood cell count and differential count in our hospital between January 2006 and March 2013. Eosinophil count was measured using SE-5000 and SE-2100 (Sysmex, Kobe, Japan). The patients with an eosinophil count of 2000/mL were enrolled and examined for their maximum eosinophil count, diagnosis of eosinophilia-related disease, and steroid dose at the sampling for the maximum count. For each patient's disease course, the maximum eosinophil count was used in the analysis regardless of treatment. The diagnoses were based on clinical records. According to their diagnoses, the patients were classified into ten groups: skin diseases including atopic dermatitis and urticaria, NEAE, solid tumors including lung cancer, digestive tract cancer, hepatobiliary cancer, pancreas cancer, brain cancer, breast cancer, uterus cancer and renal cancer, hematological tumors including leukemia, lymphoma, multiple myeloma, amyloidosis, myelodysplastic syndromes and idiopathic thrombocytopenic purpura, bronchial asthma, eosinophilic granulomatosis with polyangiitis (EGPA), mono-organ involvement associated with eosinophilia, drug reactions including drug-induced eruption and hepatitis, parasitic diseases, and others. As for patients with solid or hematological tumor, if their peripheral eosinophilia were clearly related to the side effect of their treatment, they were classified into drug reactions. Mono-organ involvement associated with eosinophilia was defined as an organ injury considered to be caused by eosinophilic infiltration.
During the study period, 845439 blood samples were examined. Among these samples, 1137 (0.13%) showed an eosinophil count of 2000/mL and 62 (0.007%) showed a count of 10000/ mL. As for samples with a count of 2000/mL, the number of samples at each 1000/mL interval is shown in Figure 1 . 1134 samples with a count of 2000/mL were from 442 patients (248 males and 194 females) aged 63.1 ± 17.3. The ratios of disease in patients with an eosinophil count of 2000/mL and 10000/mL are shown in Figure 2 . The number of patients and mean ± SD maximum eosinophil count in each of ten groups were as follows: n ¼ 70, 3676 ± 3018/mL in skin diseases; n ¼ 68, 3275 ± 3376/mL in solid tumors; n ¼ 51, 4631 ± 3217/mL in drug reactions; n ¼ 37, 3808 ± 2355/mL in hematological tumors; n ¼ 36, 5711 ± 3332/mL in mono-organ involvement associated with eosinophilia (pneumonia; 66.7%, gastroenteritis; 8.3%, sinusitis; 8.3%, serositis; 5.6%, myocarditis; 5.6%, others; 5.6%); n ¼ 23, 8412 ± 8121/mL in NEAE; n ¼ 16, 8290 ± 6428/mL in EGPA; n ¼ 15, 2919 ± 1157/mL in bronchial asthma; n ¼ 6, 3898 ± 1821/mL in parasitic diseases; and n ¼ 116, 3291 ± 2065/mL in others. Others consist mainly of transient eosinophilia of unknown causes during treatment of various diseases. Only 28 patients showed a maximum count of 10000/mL; the major diagnoses were EGPA (n ¼ 7, 25.0%), NEAE (n ¼ 4, 14.3%), and mono-organ involvement associated with eosinophilia (n ¼ 5, 17.8%). As for the steroid regimen, among the 442 patients with eosinophil counts of 2000/mL, 49 patients (11.1%) were administered prednisolone (PSL) (1.3 ± 5.0 mg/day) at the sampling, and 34 (8.2%) had PSL at a dose of 5 mg/day.
This study was focused on the severity of the peripheral blood eosinophilia. Among over the 800000 samples, only 0.13% of samples showed an eosinophil count of 2000/mL, and only 0.007% showed a count of 10000/mL. An eosinophil count of 10000/ mL was associated with a few diseases, namely EGPA, NEAE and mono-organ involvement associated with eosinophilia. For the differential diagnosis of HEADs, an eosinophil count of 10000/ Peer review under responsibility of Japanese Society of Allergology.
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Allergology International j o u r n a l h o me p a g e : h t t p : / / w w w . e l se v i e r . c o m / l o c a t e / a l i t mL may indicate an initial probable diagnosis of one of the abovementioned diseases. On the other hand, patients with an eosinophil count of 2000e10000/mL have more differential diagnoses than a count of 10000/mL. In this study, more than half of patients with a count of 2000/mL belonged to the groups of skin diseases, drug reactions and solid/hematological tumors. This result suggests patients with an eosinophil count of 2000e10000/mL firstly should exclude skin diseases, drug reactions and solid/hematological tumors.
Bronchial asthma rarely develops with severe eosinophilia reaching to a count of 2000/mL, but this study included 15 cases. Among 15 cases, four cases were examined at the asthmatic attack and eight cases were complicated with other diseases. Only three cases were examined without the attack or other diseases.
Conceivably in developing countries, severe eosinophilia might be often associated with parasitic diseases. 7 But currently, parasitic diseases seldom develop in Japan. 8 Our hospital is a general hospital, to which many patients with various diseases visit, but only six of the 442 patients had eosinophilia related to parasitic diseases.
The peripheral blood eosinophil count during the treatment of corticosteroids, which usually decrease it, is not appropriate for the argument about the usefulness of the count. 9 However, in this study, the maximum eosinophil count was observed without steroid therapy in almost 90% of the patients, and only a few had 5 mg of PSL at the sampling. The use of corticosteroids would not be a limitation of this study.
In conclusion, a peripheral blood eosinophil count of 10000/mL was observed only in a limited number of patients and in a few diseases, mainly EGPA, NEAE and mono-organ involvement associated with eosinophilia. It is useful to evaluate the maximum eosinophil count for the presumptive diagnosis of HEADs. 
